• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Cullinan Therapeutics, Inc.

    Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CGEM
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.